Tenaya Therapeutics (TNYA) Other Accumulated Expenses (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Other Accumulated Expenses of $455000.0 for Q1 2026, up 30.0% year-over-year from $350000.0 in Q1 2025, and up 158.52% quarter-over-quarter from $176000.0 in Q4 2025.
Tenaya Therapeutics (TNYA) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $455000.0 for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 30.0% year-over-year to $455000.0; the TTM figure through Mar 2026 stood at $455000.0 (up 30.0% YoY), while the FY2025 annual figure was $176000.0, down 17.76% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $455000.0, up from $176000.0 in the prior quarter.
- The five-year high for Other Accumulated Expenses was $833000.0 in Q1 2024, with the low at $142000.0 in Q2 2025.
- The 5-year median for Other Accumulated Expenses is $458000.0 (2023), against an average of $463117.6.
- The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses jumped 236.42% in 2022, then tumbled 63.75% in 2024.
- Tenaya Therapeutics' Other Accumulated Expenses stood at $545000.0 in 2022, then declined by 12.29% to $478000.0 in 2023, then sank by 55.23% to $214000.0 in 2024, then retreated by 17.76% to $176000.0 in 2025, then soared by 158.52% to $455000.0 in 2026.
- Business Quant data shows TNYA's Other Accumulated Expenses at $455000.0 in Q1 2026, $176000.0 in Q4 2025, and $186000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tenaya Therapeutics | 151.50 Mn | 151.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 324,000.00 |
| Mar 31, 2026 | 455,000.00 |
| Dec 31, 2025 | 176,000.00 |
| Sep 30, 2025 | 186,000.00 |
| Jun 30, 2025 | 142,000.00 |
| Mar 31, 2025 | 350,000.00 |
| Dec 31, 2024 | 214,000.00 |
| Sep 30, 2024 | 435,000.00 |
| Jun 30, 2024 | 282,000.00 |
| Mar 31, 2024 | 833,000.00 |
| Dec 31, 2023 | 478,000.00 |
| Sep 30, 2023 | 458,000.00 |
| Jun 30, 2023 | 778,000.00 |
| Mar 31, 2023 | 677,000.00 |
| Dec 31, 2022 | 545,000.00 |
| Sep 30, 2022 | 485,000.00 |
| Jun 30, 2022 | 588,000.00 |
| Mar 31, 2022 | 791,000.00 |
| Dec 31, 2021 | 162,000.00 |
| Sep 30, 2021 | 514,000.00 |